Eicosapentaenoic And Docosahexaenoic Acids Attenuate Progression Of Albuminuria In Patients With Type 2 Diabetes Mellitus And Coronary Artery Disease
Notes for this study:
||For everyone, measured as change in percent of people with albumin-to-creatinine ratio (ACR) of at least 30 mcg/mg after one year: 75% increase in control group, 10% increase in treatment group. P = 0.167 For just people with type 2 diabetes, measured as change in ACR after a year: 14.6 in control group, 4.63 in treatment group. P = 0.04. For just people without type 2 diabetes, measured as change in ACR after a year: 4.29 in control group, -5.85 in treatment group. P = 0.56.
|Number of Subjects
This study analyzed the prespecified secondary endpoint of a previously run trial. The endpoint examined here was albumin in the urine as a marker of kidney function in people with stable coronary artery disease (CAD) who were treated with either nothing or 4 Loveza capsules daily (1.86 g EPA + 1.5 g DHA daily as ethyl esters) for a year. There was no overall significant effect. However, there was a borderline significant effect in people with diabetes, most of whom were also being treated with an ACE inhibitor or ARB and all of whom were taking a statin and aspirin.
Funding issues for this study:
Lovaza provided by Glaxo SmithKline.